Education
About Us
Working with TipRanks
Follow Us
Spruce Biosciences, Inc. (SPRB)
OTHER OTC:SPRB
See the Price Targets and Ratings of:
SPRB Financial Forecast
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Leerink Partners
$1
Hold
-89.98%
Downside
Reiterated
05/07/25
Analysts Offer Insights on Healthcare Companies: Adicet Bio (NASDAQ: ACET) and Spruce Biosciences (Other OTC: SPRB)We are updating our model to reflect SPRB's 1Q25 financial results and corporate update; the BLA for tralesinidase alfa for the treatment of Sanfilippo Syndrome Type B (MPS IIIB) remains on track for 1H26. Following the strategy update last month (Pipeline but MP), SPRB is focused on advancing tralesinidase alfa, an enzyme replacement therapy (ERT), for the treatment of MPS IIIB. the FDA confirmed in a Type C meeting that HS-NRE (heparan sulfate non-reducing end) is deemed to be a surrogate biomarker reasonably likely to predict clinical benefit and could serve as a basis for Accelerated Approval. The company continues to guide to a Biologics License Application (BLA) submission in the first half of 2026.
RBC Capital
$0.5
Hold
-94.99%
Downside
Reiterated
05/06/25
H.C. Wainwright
―
Hold
―
Reiterated
04/28/25
Citizens JMP
―
Hold
―
Reiterated
04/23/25
Oppenheimer
―
Hold
―
Downgraded
12/11/24
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Leerink Partners
$1
Hold
-89.98%
Downside
Reiterated
05/07/25
Analysts Offer Insights on Healthcare Companies: Adicet Bio (NASDAQ: ACET) and Spruce Biosciences (Other OTC: SPRB)We are updating our model to reflect SPRB's 1Q25 financial results and corporate update; the BLA for tralesinidase alfa for the treatment of Sanfilippo Syndrome Type B (MPS IIIB) remains on track for 1H26. Following the strategy update last month (Pipeline but MP), SPRB is focused on advancing tralesinidase alfa, an enzyme replacement therapy (ERT), for the treatment of MPS IIIB. the FDA confirmed in a Type C meeting that HS-NRE (heparan sulfate non-reducing end) is deemed to be a surrogate biomarker reasonably likely to predict clinical benefit and could serve as a basis for Accelerated Approval. The company continues to guide to a Biologics License Application (BLA) submission in the first half of 2026.
RBC Capital
$0.5
Hold
-94.99%
Downside
Reiterated
05/06/25
H.C. Wainwright
―
Hold
―
Reiterated
04/28/25
Citizens JMP
―
Hold
―
Reiterated
04/23/25
Oppenheimer
―
Hold
―
Downgraded
12/11/24
SPRB Analyst Recommendation Trends
Rating
Nov 24
Dec 24
Jan 25
Apr 25
May 25
Strong Buy
0
0
0
0
0
Buy
2
3
2
2
0
Hold
7
10
10
11
7
Sell
2
4
5
4
2
Strong Sell
0
0
0
0
0
total
11
17
17
17
9
Each month's total comprises the sum of three months' worth of ratings.
SPRB Stock Forecast FAQ
What is SPRB’s average 12-month price target, according to analysts?
Based on analyst ratings, Spruce Biosciences, Inc.’s 12-month average price target is 0.75.
What is SPRB’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for SPRB, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is SPRB a Buy, Sell or Hold?
Spruce Biosciences, Inc. has a consensus rating of Hold which is based on 0 buy ratings, 0 hold ratings and 0 sell ratings.
What is Spruce Biosciences, Inc.’s price target?
The average price target for Spruce Biosciences, Inc. is 0.75. This is based on 0 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $1.00 ,the lowest forecast is $0.50. The average price target represents -92.48% Decrease from the current price of $9.98.
The highest analyst price target is $1.00 ,the lowest forecast is $0.50. The average price target represents -92.48% Decrease from the current price of $9.98.
What do analysts say about Spruce Biosciences, Inc.?
Spruce Biosciences, Inc.’s analyst rating consensus is a Hold. This is based on the ratings of 0 Wall Streets Analysts.
How can I buy shares of SPRB?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.